|
|
|
|
|
| Type size: |
 |
 |
|
|
Scientific Advisory Board
The scientific advisory board at Monogram is made up of renowned leaders in the fields of HIV, oncology and serious diseases. Based on their diverse qualifications, each of these individuals provides a unique perspective on the challenges and trends in the management of these diseases.
- David B. Agus, MD
- Carlos L. Arteaga, MD
- Jose Baselga, MD
- Stephen P. Goff, PhD
- Roy S. Herbst, MD, PhD
- Manuel Hidalgo, MD, PhD
- David D. Ho, MD
- Douglas D. Richman, MD
- Robert T. Schooley, MD
- PJ Utz, MD
- Owen N. Witte, MD
David B. Agus, MD is Research Director at the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and Assistant Professor of Medicine at UCLA. Dr. Agus's research focuses on the biology of cancer and the development of new treatments for prostate cancer.
Carlos L. Arteaga, MD is Professor of Medicine and Cancer Biology and Director of the Breast Cancer Research Program of the Vanderbilt-Ingram Cancer Center at Vanderbilt University School of Medicine. Professor Arteaga's research focuses on the role of growth factor receptors, such as the EGF receptor, erb-B2 and TGF-beta receptors in the progression of breast cancer, as well as the development of anti-cancer molecular therapeutics.
Jose Baselga, MD is Professor of Medicine at the Universidad Autonoma de Barcelona and the Scientific Chairman of the Spanish Breast Cancer cooperative group SOLTI. Dr. Baselga's research interests are in clinical breast cancer and in the area of growth factor receptors and downstream molecules as targets for cancer therapy.
Stephen P. Goff, PhD is the Higgins Professor of Biochemistry and Molecular Biophysics at the College of Physicians and Surgeons of Columbia University, and an Investigator of the Howard Hughes Medical Institute. Dr. Goff received his PhD in biochemistry at Stanford University with Nobel Laureate Paul Berg, and his postdoctoral training in the laboratory of Nobel Laureate David Baltimore. Dr. Goff is a world-recognized expert on the replication of retroviruses, including HIV, and is widely known for his pioneering studies on the effects of mutations upon retroviruses.
Roy S. Herbst, MD, PhD is Chief of the Section of Thoracic Oncology and Associate Professor at the University of Texas M. D. Anderson Cancer Center in Houston. Dr. Herbst is a leading researcher in the field of novel anti-angiogenic/anti-metastatic translational drug development with primary research areas focused on the biology and treatment of lung and head and neck cancer, prognostic markers in lung cancer, and the clinical development of new anti-angiogenesis agents.
Manuel Hidalgo, MD, PhD is an Associate Professor of Oncology and Co-Director of the Drug Development Program at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Hidalgo is considered a leading researcher in the development of targeted therapies for the treatment of cancer in patients with solid tumors. His research focuses on optimizing the clinical development of novel treatments by measuring target receptor and molecular anomalies, as well as analyzing biological activity in the tumor and normal tissues of patients treated with specific therapies.
David D. Ho, MD is the Scientific Director and Chief Executive Officer of the Aaron Diamond AIDS Research Center in New York and a Professor at The Rockefeller University. Dr. Ho received his MD from Harvard Medical School and his postdoctoral training at Massachusetts General Hospital and Harvard Medical School. Dr. Ho is world-renowned for his pioneering studies on the dynamics of HIV infection and its effects upon the human immune system, and is an expert on antiviral drug therapy for HIV.
Douglas D. Richman, MD is a Professor of Pathology and Medicine at the University of California, San Diego School of Medicine, and the Director of the Research Center for AIDS and HIV Infection at the San Diego VA Medical Center. Dr. Richman received his MD from Stanford University and his postdoctoral training at the National Institutes of Health and at Harvard Medical School. Dr. Richman is a leading AIDS clinical investigator, having directed the clinical trial resulting in the approval of AZT by the FDA; was the first to discover HIV drug resistance; and is considered by many to be the world's leading expert on HIV drug resistance.
Robert T. Schooley, MD is Professor and Head of the Division of Infectious Diseases of the University of California, San Diego. Dr. Schooley received his MD from Johns Hopkins University School of Medicine and his postdoctoral training at the NIH and Massachusetts General Hospital. He has served as Chair of the NIH's AIDS and Related Retrovirus Study Section and as Chair of the Executive Committee of the NIAID's AIDS Clinical Trials Group (ACTG). Dr. Schooley's interests are in the areas of viral pathogenesis and therapy.
PJ Utz, MD is an Assistant Professor and directs a research laboratory in the Division of Rheumatology and Immunology at the Center for Clinical Immunology at the Stanford University School of Medicine. Dr. Utz's research is focused on autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis.
Owen N. Witte, MD is Professor of Microbiology, Immunology and Molecular Genetics at UCLA. Professor Witte is also an Investigator of the Howard Hughes Medical Institute. Professor Witte's research focuses on the interrelated problems of cell growth regulation and differentiation and the understanding of the function of oncogenes found in human leukemia and epithelial cancer, as well as immune disorders and inflammation.
|
|
 |
|
